We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Quality, Not Quantity, Important in Immune Control of HIV

By Biotechdaily staff writers
Posted on 17 Oct 2002
A recent study found there was no significant difference in the number of HIV-fighting CD8+ cells between nonprogressors, people who have controlled HIV for up to 20 years without antiretroviral therapy, and others (progressors). More...
The report appeared October 7, 2002, in the advanced online issue of Nature Immunology.

Previously, it had been thought that people who could not control HIV had too few CD8+ T cells. The current study showed, however, that both nonprogressors and others have about the same number of CD8+ T cells, but the cells of nonprogressors function better. Furthermore, CD8+ T cells from nonprogessors produce higher levels of perforin. Perforin (cytolysin) is believed to be one of the major effector molecules used by cytotoxic T cells to mediate targeted cell lysis.

The investigators' from the National Institute of Allergy and Infectious Diseases (NIAID, Bethesda, MD, USA; www.nih.gov), examined the immune systems of 40 people infected with HIV, including a group of about 15 nonprogressors. "Some of the newer techniques used in this study enabled us to see the functional differences in the CD8+ T cells of the two groups,” explained lead author Dr. Stephen Migueles. "The CD8+ T cells of people in the study who did not control HIV had retained only a limited ability to divide and produce perforin.”

"Understanding the mechanisms by which the immune systems of long-term nonprogressors control HIV is important to our development of effective vaccines,” said Dr. Anthony S. Fauci, director of the NIAID. "Studies like this one, which reveal basic knowledge about how the immune system interacts with HIV, form the foundation of our effort to fight this disease.”




Related Links:
National Inst of Allergy and Infectious Diseases

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.